Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1995-2-16
|
| pubmed:abstractText |
Twenty-four fresh tumors of gastric carcinoma were assessed by flow cytometric detection of P-glycoprotein (P-gp) using monoclonal antibody C219. Eight patients were P-gp positive. Differentiated gastric carcinomas contained significantly higher concentrations of P-gp positive. Incidence of P-gp positive was high in advanced stage. In 16 cases estimated chemosensitivity was test assessed by thymidine incorporation assay (TIA). Seven of nine multidrug-resistant cases according to TIA were P-gp positive and all of seven nonmultidrug resistant cases were P-gp negative. Expression of P-gp and multidrug resistance were closely correlated (P < 0.01). Also, in 89 patients with operable gastric carcinoma, the relation between in vitro chemosensitivity test (TIA) and their clinicopathologic features as well as their survival lengths were studied. Thirty-one of 89 specimens from gastric carcinoma patients were multidrug resistant according to TIA. Patients in the multidrug-resistant group had a significantly poorer cumulative survival rate than those who were not multidrug resistant (P < .05). The multivariate analysis showed that multidrug resistance is a useful indicator of prognosis (P < 0.1). We suggest that multidrug-resistant cases or P-gp-positive cases of gastric carcinoma are highly malignant, and these determinations are clinically useful.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0022-4790
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
58
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
63-9
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7823576-Adult,
pubmed-meshheading:7823576-Aged,
pubmed-meshheading:7823576-Aged, 80 and over,
pubmed-meshheading:7823576-Antibodies, Monoclonal,
pubmed-meshheading:7823576-Carcinoma,
pubmed-meshheading:7823576-Drug Resistance, Multiple,
pubmed-meshheading:7823576-Drug Screening Assays, Antitumor,
pubmed-meshheading:7823576-Female,
pubmed-meshheading:7823576-Flow Cytometry,
pubmed-meshheading:7823576-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:7823576-Humans,
pubmed-meshheading:7823576-Male,
pubmed-meshheading:7823576-Middle Aged,
pubmed-meshheading:7823576-Multivariate Analysis,
pubmed-meshheading:7823576-P-Glycoprotein,
pubmed-meshheading:7823576-Predictive Value of Tests,
pubmed-meshheading:7823576-Prognosis,
pubmed-meshheading:7823576-Retrospective Studies,
pubmed-meshheading:7823576-Stomach Neoplasms,
pubmed-meshheading:7823576-Survival Analysis,
pubmed-meshheading:7823576-Thymidine
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Clinical significance of multidrug resistance and P-glycoprotein expression in patients with gastric carcinoma.
|
| pubmed:affiliation |
Second Department of Surgery, Fukui Medical School, Japan.
|
| pubmed:publicationType |
Journal Article
|